Table 2.

MXRA5 mRNA expression in human kidney disease according to publicly available transcriptomics datasets

Group	n‐fold	P ‐value	Reference
Clear cell sarcoma of the kidney versus control	4.79	0.003	45
Focal segmental glomerulosclerosis versus normal kidney/minimal change disease	4.58	0.001	21
Diabetic nephropathy versus healthy living donor (glomeruli)	1.96	0.05	46
Lupus Nephritis versus healthy living donor (tubulointerstitium)	1.75	0.043	47
Diabetic nephropathy versus minimal change disease	1.53	0.029	48
Rapidly progressive glomerulonephritis versus healthy living donor/minimal change disease (glomeruli)	1.48	0.018	49
Diabetic nephropathy versus healthy living donor/minimal change disease	1.47	0.008	49
Renal dysfunction versus healthy living donor	1.24	0.003	50

No significant differences were found for nephrosclerosis: glomeruli versus healthy glomeruli from tumour‐free nephrectomy specimens 51 or for renal cell carcinoma versus adjacent non‐tumour tissue 52.